Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bonora

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
HIV Medicine|May 16, 2018
Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disordersM Trunfio, D Vai, C Montrucchio, et al.
Infection|December 3, 2011
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot studyS Bonora, A Calcagno, C Cometto, et al.
Transplantation Proceedings|June 8, 2006
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantationG Guaraldi, S Cocchi, M Codeluppi, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infectionsI Motta, M Trunfio, A Calcagno, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 3, 2017
Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015B Rossetti, F Bai, A Tavelli, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 27, 2015
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three casesE Righi, A Londero, F Pea, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical settingD González de Requena, S Bonora, S Garazzino, et al.
Journal of Neurovirology|January 19, 2022
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disordersA Barco, S Orlando, G Stroffolini, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 7, 2009
Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplantG Guaraldi, S Cocchi, A Motta, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
HIV Medicine|May 16, 2018
Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disordersM Trunfio, D Vai, C Montrucchio, et al.
Infection|December 3, 2011
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot studyS Bonora, A Calcagno, C Cometto, et al.
Transplantation Proceedings|June 8, 2006
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantationG Guaraldi, S Cocchi, M Codeluppi, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infectionsI Motta, M Trunfio, A Calcagno, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 3, 2017
Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015B Rossetti, F Bai, A Tavelli, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 27, 2015
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three casesE Righi, A Londero, F Pea, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical settingD González de Requena, S Bonora, S Garazzino, et al.
Journal of Neurovirology|January 19, 2022
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disordersA Barco, S Orlando, G Stroffolini, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 7, 2009
Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplantG Guaraldi, S Cocchi, A Motta, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.
Pageof 11